尼妥珠单抗联合同步放化疗治疗局部晚期宫颈癌患者的临床疗效

Clinical efficacy of nimotuzumab combined with concurrent chemoradiotherapy in patients with locally advanced cervical cancer

目的探讨尼妥珠单抗联合同步放化疗治疗局部晚期宫颈癌患者的临床疗效。方法根据治疗方法的不同将72例局部晚期宫颈癌患者分为对照组(n=30,同步放化疗)和观察组(n=42,尼妥珠单抗联合同步放化疗)。比较两组患者的临床疗效、T淋巴细胞亚群(CD4^(+)、CD8^(+))水平、肿瘤标志物[肿瘤特异性生长因子(TSGF)、糖类抗原125(CA125)、鳞状细胞癌抗原(SCCA)]水平及不良反应发生情况。结果观察组患者的总有效率为90.48%,明显高于对照组患者的63.33%(P﹤0.01)。治疗后,两组患者CD4^(+)、CD8^(+)水平均低于本组治疗前,观察组患者CD4^(+)、CD8^(+)水平均高于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者TSGF、CA125、SCCA水平均低于本组治疗前,观察组患者TSGF、CA125、SCCA水平均低于对照组,差异均有统计学意义(P﹤0.05)。两组患者各不良反应发生率比较,差异均无统计学意义(P﹥0.05)。结论尼妥珠单抗联合同步放化疗治疗局部晚期宫颈癌患者,可提高临床疗效,改善免疫功能,降低肿瘤标志物水平,且安全性较好。

Objective To investigate the clinical efficacy of nimotuzumab combined with concurrent chemoradiotherapy in patients with locally advanced cervical cancer.Method A total of 72 patients with locally advanced cervical cancer were divided into control group(n=30,received concurrent chemoradiotherapy)and observation group(n=42,received nimotuzumab combined with concurrent chemoradiotherapy)according to different treatment methods.The clinical efficacy,T lymphocyte subsets(CD4^(+),CD8^(+))levels,tumor markers[tumor specific growth factor(TSGF),carbohydrate antigen 125(CA125),squamous cell carcinoma antigen(SCCA)]levels and the occurrence of adverse reactions were compared between the two groups.Result The total effective rate of the observation group was 90.48%,significantly higher than 63.33%of the control group(P<0.01).After treatment,the levels of CD4^(+)and CD8^(+)in both groups were lower than those before treatment,and the levels of CD4^(+)and CD8^(+)in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the TSGF,CA125 and SCCA levels in both groups were lower than those before treatment,and the TSGF,CA125 and SCCA levels in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Nimotuzumab combined with concurrent chemoradiotherapy in the treatment of local advanced cervical cancer patients can improve clinical efficacy and immune function,reduce the level of tumor markers,and have high safety.